Importation of Medicinal Products
Annex 21 sets GMP requirements for holders of a manufacturing/import authorisation (MIA) that import medicinal products from outside the EU/EEA. It clarifies the responsibilities that must be performed within the EU/EEA — importation, QP certification, and the associated quality-system oversight — and the documentation, premises, and control activities expected at the site of physical importation and the site of QP certification.
What this does not cover
stated in the document's own scope- Does not cover product manufactured and released within the EU/EEA
- Does not itself define QP certification duties in full — see Annex 16
- Does not remove importation testing except where an MRA or equivalent basis applies
- Does not address wholesale distribution requirements — see the EU GDP guidelines
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Annex 21 of the EU GMP Guide sets GMP requirements for the importation of medicinal products into the EU/EEA by holders of a manufacturing and import authorisation (MIA). It clarifies which activities must take place within the EU/EEA — physical importation and Qualified Person (QP) certification — and the responsibilities of the sites performing them. It covers the pharmaceutical quality system, premises and equipment, documentation, and the handling of imported product, whether for further processing, for QP certification, or for other purposes. It applies to human, veterinary, and investigational medicinal products imported from third countries.
Legal basis & how it acquires force
Annex 21 forms part of EudraLex Volume 4 and gives operational effect to the GMP and importation obligations in EU medicines legislation (Directive 2001/83/EC and 2001/82/EC and their implementing acts). It is binding on MIA holders performing importation, and QP certification of imported batches must occur within the EU/EEA in accordance with the annex and Annex 16.
Document structure
| Part | Covers |
|---|---|
| Scope | Products and activities covered; importation from outside the EU/EEA |
| Pharmaceutical quality system | PQS responsibilities of the importing MIA holder |
| Premises and equipment | Requirements at the physical importation site |
| Documentation | Records supporting importation and QP certification |
| Operations / responsibilities | Physical importation site vs QP certification site duties |
Key requirements
- Hold a valid MIA covering importation for the site performing import activities
- Perform QP certification of each imported batch within the EU/EEA
- Distinguish and document the physical importation site and the QP certification site responsibilities
- Maintain a pharmaceutical quality system covering the imported product and its supply chain
- Ensure importation testing arrangements or a mutual recognition agreement (MRA) basis are in place
- Retain documentation and samples as required for imported batches
- Apply the same GMP standard to imported product as to product manufactured in the EU/EEA
Implementation tips
- Map exactly which activities occur at which site; Annex 21 is precise about where each must happen
- Confirm whether an MRA covers your importing route before assuming import testing can be waived
- Ensure the QP has full access to the third-country manufacturing and testing records
- Read Annex 21 with Annex 16 (QP certification and batch release) — they are complementary
International alignment
Annex 21 is an EU/EEA GMP standard. It operates together with Annex 16 (QP certification and batch release) and relies on the EU framework of mutual recognition agreements (MRAs) that can affect importation testing obligations for products from partner countries.
EU GMP Annex 21: frequently asked questions
Quick answers to common questions about EU GMP Annex 21.
Where must QP certification of an imported batch occur?
Within the EU/EEA, by a QP of the importing MIA holder, per Annex 21 and Annex 16.
Does Annex 21 apply to investigational medicinal products?
Yes; its scope includes human, veterinary, and investigational medicinal products imported from third countries.
Are the physical import site and QP certification site necessarily the same?
No. The annex distinguishes their responsibilities and they may be different sites.